Chemical Oxidative Polymerization of Methylene Blue: Reaction Mechanism and Aspects of Chain Structure.

The kinetic regularities of the initial stage of chemical oxidative polymerization of methylene blue under the action of ammonium peroxodisulfate in an aqueous medium have been established by the method of potentiometry. It was shown that the methylene blue polymerization mechanism includes the stages of chain initiation and growth. It was found that the rate of the initial stage of the reaction obeys the kinetic equation of the first order with the activation energy 49 kJ × mol.

[Bone mineral density in patients with scleroderma systematica].

Aim: To study the frequency and magnitude of a reduction in bone mineral density (BMD) and its association with clinical parameters in patients with scleroderma systematica (SDS).

Subjects And Methods: Fifty-six postmenopausal women aged 45-71 years (58.1±7.

[Angiogenesis and its association with inflammation and fibrosis in course of the development of scleroderma systematica].

Scleroderma systematica (SDS) is a chronic autoimmune disease characterized by severe fibrosis of the skin and visceral organs. Vascular disorders are an important component of the disease, but the mechanisms of vascular injury and their prevention are unknown. Angiogenesis in SDS is accompanied by the apparent expression of angiogenic factors, such as vascular endothelial growth factor and basal or fibroblast growth factor.

[Efficacy and safety of sildenafil in patients with systemic scleroderma].

Aim: To retrospectively analyze the efficacy and safety of sildenafil (Sf) in patients with systemic sclerosis (SS).

Subjects And Results: Sf was used in 16 patients (including 14 women) aged 20-66 years (mean 48.6 +/- 14.

[Pleiotropic effects of statins in systemic sclerosis].

Aim: To study anti-inflammatory and angioprotective properties of statins in patients with systemic sclerosis (SS).

Material And Methods: Fifty SS patients enrolled in the trial were divided into two groups: the study group included 30 patients who received standard therapy and atorvastatin in a dose 10-40 mg/day, the control group (n = 20) received standard therapy alone. The blood of the patients was studied with enzyme immunoassay for concentrations of highly sensitive C-reactive protein (hs-CRP), IL-6, VCAM-1, E-selectin, WF antigen, VEGF-A, VEGF-R2.